Welcome to our dedicated page for Polydex Pharmaceuticals news (Ticker: POLXF), a resource for investors and traders seeking the latest updates and insights on Polydex Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Polydex Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Polydex Pharmaceuticals's position in the market.
Polydex Pharmaceuticals Limited (OTC Pink: POLXF) reported its Q3 fiscal 2022 results, revealing sales of $1,096,360, down from $1,228,855 in Q3 2021. The company faced a net loss of $68,676, contrasting with a profit of $23,607 in the previous year. Despite these challenges, management emphasized prudent cash management and ongoing efforts to explore new markets for their products, particularly in industrial applications for Native Dextran. The effects of the COVID pandemic and African Swine Fever continue to impact sales significantly.
Polydex Pharmaceuticals Limited (OTC Pink: POLXF) has released its financial results for the second quarter of fiscal 2022, revealing sales of $1,340,644, a slight decrease from $1,377,747 in Q2 2021. The company reported a net loss of $33,035, compared to a profit of $64,462 in the same period last year. Despite challenges from Covid-19 and African Swine Fever affecting demand, management expressed cautious optimism regarding improvements in iron dextran sales and ongoing efforts to explore new markets. The company remains committed to cash management strategies during this period.
Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) reported its Q1 fiscal 2022 results, showing sales of $846,893, a slight increase from $839,322 in Q1 2021. However, the company faced a net loss of ($195,407), down from a profit of $58,339 in the previous year. The loss per share was ($0.06) compared to $0.02 earnings last year. The company attributed challenges to the ongoing effects of African Swine Fever and a strong Canadian dollar. Despite these issues, management highlighted its focus on careful cash management and expansion into new markets.
Polydex Pharmaceuticals Limited (Pink Sheets: POLXF) reported its financial results for the fiscal year ended January 31, 2021. Total sales were $4,856,169, a decline from $5,141,341 in 2020. Net income fell to $211,702, down from $250,886 year-over-year. Despite challenges, management noted strong performance in the order book for fiscal 2022, particularly for native dextran products. The company remains profitable during the pandemic and has successfully managed its operations without layoffs. Future orders are expected to bolster sales in the coming quarters.